Regeneron Pharmaceuticals, Inc. (ETR:RGO)
Germany · Delayed Price · Currency is EUR 495.40
+3.10 (0.63%)
At close: Oct 10, 2025
Regeneron Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | 4,459 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade |
Depreciation & Amortization | 510 | 482.8 | 421 | 341.4 | 286.2 | 235.9 | Upgrade |
Stock-Based Compensation | 1,037 | 982.8 | 885 | 725 | 601.7 | 432 | Upgrade |
Other Adjustments | -1,026 | -839.5 | -571.5 | -146.6 | 34.6 | -59.4 | Upgrade |
Change in Receivables | 122.9 | -554 | -338.8 | 707.8 | -1,927 | -1,356 | Upgrade |
Changes in Inventories | -476.9 | -619.7 | -271.7 | -696.5 | -494.3 | -529.4 | Upgrade |
Changes in Unearned Revenue | -103.4 | 227.8 | 37.9 | 32.4 | -120.2 | 148.1 | Upgrade |
Changes in Other Operating Activities | 208.8 | 327.6 | 478.5 | -287 | 625.4 | 233.8 | Upgrade |
Operating Cash Flow | 4,744 | 4,421 | 4,594 | 5,015 | 7,081 | 2,618 | Upgrade |
Operating Cash Flow Growth | 16.53% | -3.78% | -8.39% | -29.18% | 170.47% | 7.74% | Upgrade |
Capital Expenditures | -889.8 | -755.9 | -718.6 | -590.1 | -551.9 | -614.6 | Upgrade |
Sale of Property, Plant & Equipment | - | 20.1 | - | - | - | - | Upgrade |
Purchases of Intangible Assets | - | -125.7 | -207.8 | -1,027 | - | - | Upgrade |
Purchases of Investments | -11,938 | -16,617 | -11,646 | -7,488 | -7,048 | -3,241 | Upgrade |
Proceeds from Sale of Investments | 12,467 | 15,027 | 9,442 | 5,551 | 2,215 | 3,785 | Upgrade |
Payments for Business Acquisitions | - | -16.5 | -54.9 | -230.3 | - | - | Upgrade |
Investing Cash Flow | -670.3 | -2,468 | -3,185 | -3,785 | -5,385 | -70.6 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 3,482 | Upgrade |
Long-Term Debt Repaid | - | - | - | - | - | -1,500 | Upgrade |
Net Long-Term Debt Issued (Repaid) | - | - | - | - | - | 1,982 | Upgrade |
Issuance of Common Stock | 437.7 | 1,465 | 1,146 | 1,520 | 1,672 | 2,575 | Upgrade |
Repurchase of Common Stock | -4,195 | -3,632 | -2,936 | -2,529 | -2,678 | -6,528 | Upgrade |
Net Common Stock Issued (Repurchased) | -3,757 | -2,167 | -1,790 | -1,009 | -1,006 | -3,952 | Upgrade |
Other Financing Activities | - | -33.4 | - | - | - | - | Upgrade |
Financing Cash Flow | -3,987 | -2,201 | -1,790 | -1,009 | -1,006 | -1,971 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1.1 | -0.7 | -0.4 | - | - | - | Upgrade |
Net Cash Flow | 87.4 | -248.8 | -381.6 | 221.3 | 690.8 | 577 | Upgrade |
Beginning Cash & Cash Equivalents | 1,928 | 2,738 | 3,119 | 2,898 | 2,207 | 1,630 | Upgrade |
Ending Cash & Cash Equivalents | 2,016 | 2,489 | 2,738 | 3,119 | 2,898 | 2,207 | Upgrade |
Free Cash Flow | 3,854 | 3,665 | 3,875 | 4,425 | 6,529 | 2,004 | Upgrade |
Free Cash Flow Growth | 5.16% | -5.44% | -12.42% | -32.23% | 225.90% | 0.15% | Upgrade |
FCF Margin | 27.11% | 25.80% | 29.54% | 36.35% | 40.63% | 23.58% | Upgrade |
Free Cash Flow Per Share | 34.29 | 31.84 | 34.08 | 38.99 | 58.19 | 17.41 | Upgrade |
Levered Free Cash Flow | 3,707 | 4,075 | 3,901 | 3,139 | 7,821 | 4,969 | Upgrade |
Unlevered Free Cash Flow | 2,808 | 3,452 | 3,753 | 2,852 | 7,402 | 2,214 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.